Literature DB >> 33400834

Molecular requirements for human lymphopoiesis as defined by inborn errors of immunity.

Erika Della Mina1,2, Antoine Guérin1,2, Stuart G Tangye1,2.   

Abstract

Hematopoietic stem cells (HSCs) are the progenitor cells that give rise to the diverse repertoire of all immune cells. As they differentiate, HSCs yield a series of cell states that undergo gradual commitment to become mature blood cells. Studies of hematopoiesis in murine models have provided critical insights about the lineage relationships among stem cells, progenitors, and mature cells, and these have guided investigations of the molecular basis for these distinct developmental stages. Primary immune deficiencies are caused by inborn errors of immunity that result in immune dysfunction and subsequent susceptibility to severe and recurrent infection(s). Over the last decade there has been a dramatic increase in the number and depth of the molecular, cellular, and clinical characterization of such genetically defined causes of immune dysfunction. Patients harboring inborn errors of immunity thus represent a unique resource to improve our understanding of the multilayered and complex mechanisms underlying lymphocyte development in humans. These breakthrough discoveries not only enable significant advances in the diagnosis of such rare and complex conditions but also provide substantial improvement in the development of personalized treatments. Here, we will discuss the clinical, cellular, and molecular phenotypes, and treatments of selected inborn errors of immunity that impede, either intrinsically or extrinsically, the development of B- or T-cells at different stages. ©AlphaMed Press 2021.

Entities:  

Keywords:  gene therapy; hematopoietic stem cells; inborn errors of immunity; lymphopoiesis; primary immunodeficiency

Mesh:

Substances:

Year:  2021        PMID: 33400834     DOI: 10.1002/stem.3327

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  2 in total

1.  Atypical Autosomal Recessive AID Deficiency-Yet Another Piece of the Hyper-IgM Puzzle.

Authors:  Erika Della Mina; Stuart G Tangye
Journal:  J Clin Immunol       Date:  2022-03-25       Impact factor: 8.542

Review 2.  Resistance Mutations to BTK Inhibitors Originate From the NF-κB but Not From the PI3K-RAS-MAPK Arm of the B Cell Receptor Signaling Pathway.

Authors:  C I Edvard Smith; Jan A Burger
Journal:  Front Immunol       Date:  2021-06-10       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.